Jennifer Barrett, Associate Editor

Certain environmental conditions, such as salinity and temperature, may incite structural changes in myelin sheaths.

New data from the investigational multiple sclerosis (MS) drug evobrutinib showed that the therapy reduced lesions and decreased annual relapse rates in patients with relapsing MS.

A post hoc analysis of clinical trial data showed oral ozanimod improved cognitive processing speed and reduced annualized relapse rates and MRI lesions in multiple sclerosis.

Dolutegravir plus lamivudine showed non-inferiority to a 3-drug, first-line regimen in treating HIV infection.

The switchable CAR T system allows for complete control of the cancer-killing cells, which could improve the treatment’s safety.

Phase 2 data for evobrutinib shows reduction in lesions and relapse rates in patients with multiple sclerosis.

The updated label changes include information regarding use of rituximab as a follow up treatment in adults with 2 rare forms of vasculitis.

One-time, universal screening of hepatitis C virus (HCV) in the general population is cost-effective and could reduce rates of drug-related HCV cases.

Shifting Medicare Part B drugs into Part D may lead to higher costs for Medicare patients with rheumatoid arthritis, according to a new analysis.

The investigational therapy olaparib (Lynparza, AstraZeneca and Merck) has been granted Orphan Drug Designation (ODD) by the FDA for the treatment of pancreatic cancer, according to an AstraZeneca press release.

Provider-centric stigma reduction interventions can help reduce stigmatizing behaviors towards patients with HIV and potentially improve care, according to a new systematic review from the CDC.

Clinical trial demonstrates adoptive T-cell therapy may be successful in treating progressive multifocal leukoencephalopathy.

California’s tobacco control programs have lowered lung cancer deaths 33% faster than the rest of the United States.

Report analyzes HIV-related stigma among health care providers and the potential impact on quality of patient care.

Survey participants reported need for better education on how brain atrophy affects multiple sclerosis progression and cognitive loss.

Olaparib (Lynparza, AstraZeneca and Merck), which is being investigated for the treatment of prostate cancer, receives its fourth orphan drug designation from the FDA.

Officials with the FDA have approved talazoparib (Talzenna, Pfizer) for the treatment of HER2-negative locally advanced or metastatic breast cancer with germline BRCA (gBRCA) mutations.

Talazoparib, a poly ADP-ribose polymerase (PARP) inhibitor, is indicated for patients with known deleterious or suspected deleterious gBRCA-mutated breast cancer who are selected for the therapy based on an FDA-approved companion diagnostic.

Talazoparib is indicated for patients with known deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer.

Low-dose aspirin users may have a lower risk of developing ovarian cancer and hepatocellular carcinoma (HCC), according to 2 new studies published in JAMA Oncology.

Aspirin dose and duration of use may affect the risk of developing ovarian cancer and hepatocellular cancer.

Neoadjuvant therapy with a combination checkpoint blockade produced a high response rate among patients with melanoma.

Obesity and weight gain in early adulthood may be a contributor to increased risk of early-onset colorectal cancer in women under the age of 50.

Puerto Rico’s Hispanic population faces substantially different cancer risks compared with Hispanics in the continental United States.

The Department of Justice (DOJ) today granted conditional approval to the $69 billion merger between CVS Health Corporation and Aetna Inc, as long as Aetna sells its Medicare Part D prescription drug plan business.

Researchers investigated the impact of individual types of human papilloma virus on HIV acquisition.

The Department of Justice (DOJ) today granted conditional approval to the $69 billion merger between CVS Health Corporation and Aetna Inc, as long as Aetna sells its Medicare Part D prescription drug plan business.

The Department of Justice approved the $69 billion CVS-Aetna merger under conditions designed to preserve competition in the marketplace.

A new combination treatment that targets the latent reservoir of HIV may be a potential effective therapeutic strategy.

A new study has found that arthritis is commonly reported in older adults with varying degrees of depression, highlighting the importance of screening and treating arthritis-related pain in these patients.